News

CT900 is a targeted therapy that combines targeting folate receptor α (FRα) and inhibiting thymidylate synthase. The small molecule compound selectively enters cancer cells that over express folate

MEI Pharma chief medical officer Robert Mass said: “We are excited to be working with BeiGene to explore the potential of ME-401 in combination with zanubrutinib. “Combinatorial approaches

While Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor, COM701 is an investigational anti-PVRIG antibody. Apart from the clinical trial collaboration, Bristol-Myers Squibb has agreed to make

The regulator’s Oncologic Drugs Advisory Committee voted unanimously recommending approval of CT-P10, a proposed monoclonal antibody (mAb) biosimilar to Rituxan, to treat adult patients in three proposed indications.

The study is designed to evaluate MCY-M11, a mesothelin targeting CAR, in individuals with relapsed/refractory ovarian cancer and peritoneal mesothelioma. MaxCyte CEO Doug Doerfler said: “The initiation of

Silence received a notice of intention to grant from the European Patent Office for patent application EP 3 222 724B, further strengthening its innovative chemical modification technology patent

Cinfa Biotech, which was founded in 2013, has offices in Munich, Germany and Pamplona, Spain. The company, which is part of Spanish pharma firm Cinfa Group, is engaged

The collaboration will leverage Jnana’s proprietary drug discovery platform across the solute carrier (SLC) family of transporters and Neurocrine’s research and development expertise in CNS disorders to advance

The trial showed that Stelara induced clinical remission in a significantly greater proportion of UC patients at week 8 compared to placebo at both doses studied. Major secondary